What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings

Core Viewpoint - Analysts forecast Jazz Pharmaceuticals (JAZZ) to report quarterly earnings of $6.62 per share, reflecting a year-over-year increase of 0.3%, with anticipated revenues of $1.18 billion, an increase of 8.4% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 13% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts project 'Total revenues- Oncology- Vyxeos' to be $47.69 million, a decrease of 10.4% year-over-year [5]. - For 'Total revenues- Oncology- Defitelio/defibrotide', the estimate is $56.26 million, reflecting a decline of 2.4% [5]. - 'Total revenues- Neuroscience- Oxybate- Xywav' is expected to reach $448.99 million, an increase of 12% from the previous year [6]. - 'Total revenues- Neuroscience- Epidiolex/Epidyolex' is projected at $297.23 million, showing an 8.1% increase [6]. - The consensus for 'Total revenues- Neuroscience- Total' is $783.39 million, indicating a year-over-year change of 7.2% [7]. - 'Total revenues- Oncology- Total' is estimated at $322.89 million, reflecting a 10.7% increase [8]. - 'Total revenues- Oncology- Rylaze/Enrylaze' is projected at $105.81 million, suggesting a 4.3% year-over-year change [8]. - 'Total revenues- Oncology- Zepzelca' is expected to be $84.24 million, indicating a 7.6% increase [9]. - 'Revenues- Product sales, net' is anticipated to be $1.11 billion, reflecting an 8.2% increase [9]. - 'Revenues- Royalties and contract revenues' is projected at $63.75 million, indicating a 1.3% increase [9]. Stock Performance - Over the past month, Jazz shares have recorded a return of -0.3%, compared to the Zacks S&P 500 composite's -0.8% change [10]. - Based on its Zacks Rank 3 (Hold), JAZZ is expected to perform in line with the overall market in the upcoming period [10].